MedDataX Logo

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)

NCT ID: NCT01469078

Last Updated: 2012-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic Kidney Disease CKD stage 5 Iron deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

100 mg Monofer®

Group Type ACTIVE_COMPARATOR

Monofer®

Intervention Type DRUG

Single Bolus Injections

200 mg Monofer®

Group Type ACTIVE_COMPARATOR

Monofer®

Intervention Type DRUG

Single Bolus Injections

500 mg Monofer®

Group Type ACTIVE_COMPARATOR

Monofer®

Intervention Type DRUG

Single Bolus Injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monofer®

Single Bolus Injections

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women, aged more than 18 years.
2. Weight above 50 kg.
3. Subjects diagnosed with CKD-5D and on dialysis therapy for at least 90 days prior to inclusion.
4. Serum ferritin ≤ 800 ng/mL.
5. Transferrin Saturation ≤ 35%.
6. Life expectancy beyond 12 months by Principal Investigator's judgement.
7. Hb concentrations ≥10.0 g/dL and ≤12.5 g/dL both at Screening Visit 1a and at Screening Visit 1b (Screening Visit 1a and Visit 1b must be separated by at least 1 week).
8. Erythropoiesis Stimulating Agent (ESA) treatment (to be kept constant during the study period and for 4 weeks prior to inclusion with only one missed dose to be allowed during this pre-entry period).
9. Subjects in maintenance iron therapy with average iron administration ≤ 100 mg/week for 4 weeks prior to inclusion and willingness to switch to investigational product.
10. Willingness and ability to participate after informed consent (including HIPAA, if applicable).

Exclusion Criteria

1. Anemia caused primarily by other factors than renal related anemia.
2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis).
3. Difference of Hb ≥ 1.0 g/dL between Screening Visits 1a and 1b.
4. Known hypersensitivity to any excipients in the investigational drug products.
5. Subjects with a history of multiple allergies.
6. Decompensated liver cirrhosis and history of hepatitis B or C \[Alanine Aminotransferase (ALT) \> 3 times upper limit of normal\].
7. Acute or chronic infections (assessed by clinical investigator judgment), supported by White Blood Cells (WBC) and C-Reactive Protein (CRP).
8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
9. Pregnant or nursing women.
10. Women of child bearing potential who are not using safe contraceptive methods (e.g. intrauterine device, oral contraceptives or surgically sterilized) or who are planning to become pregnant within the study period.
11. Blood transfusion within the previous 12 weeks.
12. Planned elective surgery during the study where significant blood loss is expected.
13. Participation in any other clinical trial within 3 months prior to screening.
14. Untreated Vitamin B12 or folate deficiency.
15. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ClinSmart

INDUSTRY

Sponsor Role collaborator

Pharmacosmos A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P-Monofer-PK-CKD-05

Identifier Type: -

Identifier Source: org_study_id